Recurrent cannabis-induced catatonia: a case report and comprehensive systematic literature review

Background: Catatonia presents itself as a complex neuropsychiatric syndrome, giving rise to various motor, speech, and behavioral challenges. It is noteworthy that approximately 10% of psychiatric hospital admissions can be attributed to this condition. It is imperative to note that cannabis-induced catatonia, while infrequent, has been linked to the use of marijuana. This connection has the potential to disrupt neurotransmitter systems, necessitating further research for a comprehensive understanding and effective treatment, particularly given the evolving trends in cannabis use. In this context, we shall delve into a unique case of recurrent cannabis-induced catatonia.

Case presentation: A 23-year-old gentleman, who has previously struggled with substance use disorder, experienced the emergence of mutism, social isolation, and a fixed gaze subsequent to his use of cannabis. Remarkably, despite the absence of hallucinations, he exhibited recurrent episodes of catatonia. These episodes were effectively addressed through a combination of electroconvulsive therapy (ECT) and lorazepam administration. Notably, when the lorazepam dosage was gradually reduced to below 2 mg per day, the catatonic symptoms resurfaced; however, they promptly abated upon reinstating the medication. The diagnosis of cannabis-induced catatonia was established, and its management primarily involved a therapeutic approach encompassing ECT and lorazepam. It is pertinent to underscore that this catatonic condition can be directly linked to the individual’s cannabis usage.

Conclusion: The connection between cannabis and catatonia is intricate and not entirely comprehended. Although cannabis possesses therapeutic advantages, it can paradoxically trigger catatonia in certain individuals. Multiple factors, such as genetics, cannabinoids, and neurotransmitter systems, contribute to this intricacy, underscoring the necessity for additional research.

1 Introduction

Catatonia is characterized by the existence of three or more of the following features: Catalepsy, waxy flexibility, stupor, agitation, mutism, negativism, posturing, mannerisms, stereotypies, grimacing, echolalia, and echopraxia (1). Approximately 10% of all admissions to acute psychiatric facilities stem from catatonia (2). The identification of psychiatric comorbidity in mood disorders, schizophrenia, substance-related disorders, and diverse medical conditions emphasizes the multifaceted etiological factors contributing to this phenomenon (3).

Cannabis-induced catatonia constitutes a rare yet potentially grave condition in which the utilization of cannabis, colloquially known as marijuana, becomes associated with the manifestation of catatonic symptoms (4). While, generally, cannabis is deemed to carry a lower risk of inducing catatonia when juxtaposed with other substances such as stimulants or hallucinogens (5), instances have been documented where the use of cannabis coincided with the emergence of catatonic symptoms. It is crucial to recognize that this occurrence remains relatively infrequent.

The neurobiological underpinnings of catatonia are intricate and not entirely elucidated, primarily due to its heterogeneous clinical manifestations and multifarious triggers. Dysregulation of neurotransmitter systems, encompassing dopamine, GABA, and glutamate, has been implicated in the pathophysiology of catatonia (6, 7). Tetrahydrocannabinol (THC), a constituent of cannabis, exerts an impact on the endocannabinoid system, potentially disrupting the regulatory functions of GABA and glutamate (8). Certain cases have established a link between cannabis use and catatonia, particularly in instances of heightened potency and frequency of use (4). Substantial research is warranted concerning cannabis-induced catatonia, with a specific focus on comprehending its risk factors and treatment modalities. It is noteworthy that the shifting landscape of cannabis use in the United States may exert an influence on its prevalence. Extended longitudinal studies are imperative due to our limited comprehension of its prognosis and long-term repercussions.

There exist scenarios in which cannabis-induced catatonia transpires as an isolated event, while in other instances, it recurs intermittently. Within this narrative, we elucidate an atypical case of recurrent cannabis-induced catatonia.

2 Case presentation

A solitary 23-year-old male, recognized for his history of polysubstance use disorder, sought assistance at an outpatient clinic. His visit was prompted by a constellation of concerns, including mutism, reduced oral intake, self-imposed social isolation, persistent insomnia, and a sustained fixed gaze that had persisted over the preceding 10 days. The patient was accompanied by his family, who brought him to the outpatient clinic. These symptoms had surfaced subsequent to his recent use of cannabis. It is noteworthy that, despite these distressing manifestations, no evidence of delusions, auditory or visual hallucinations was discernible.

Upon the patient’s initial encounter, and after the alleviation of symptoms we undertook a meticulous evaluation of the patient’s mood to ascertain any indications of depressed mood, manic states, or mood fluctuations, we noted the presence of a partially elated mood as the only remarkable feature. With regard to anxiety-related symptoms, no discernible evidence of anxiety, excessive worry, panic attacks, or phobias was detected. Importantly, his vital signs remained well within the normal range, and there were no apparent signs of physical injury or trauma.

A review of his medical history revealed three prior admissions stemming from catatonic episodes, with the patient having undergone eight sessions of electroconvulsive therapy (ECT) over the past 2 years. The specifics of these previous hospitalizations are detailed in Table 1. Interestingly, as reported by his family members, each of these episodes had commenced prior to his cannabis use and subsequently resolved following ECT treatment. It is of particular note that during the intervals between hospitalizations, the patient remained symptom-free despite abstaining from his medications.

Table 1

Table 1. Case report timeline.

Given the patient’s current presentation marked by stupor, mutism, and negativism, we arrived at a diagnosis of retarded catatonia in accordance with the criteria set forth in DSM-5. The patient’s score on the 23-item Bush-Francis Catatonia Rating Scale was duly documented as 8. Consequently, he was admitted to the psychiatric unit for further evaluation and management.

Comprehensive laboratory investigations, including a complete blood count, electrolyte levels, liver function tests, urine analysis, and thyroid function tests, all returned within normal limits. The electrocardiogram yielded unremarkable results, and magnetic resonance imaging (MRI) revealed no structural abnormalities. Notably, in this catatonic presentation, the urine toxicology analysis confirmed the exposure to cannabinoids by returning positive for THC.

Treatment commenced with lorazepam at a dose of 1 mg, administered orally three times daily. However, after 72 h, with no discernible improvement in the patient’s condition, a decision was made to initiate ECT. Following two sessions of ECT, a marked improvement in the patient’s condition was observed, and his catatonic symptoms began to abate. Subsequently, the lorazepam dosage was reduced to 2 mg daily, administered in divided doses of 0.5 mg, 0.5 mg, and 1 mg.

In light of persistent disorganized behavior, the patient ultimately underwent a total of 8 ECT sessions over an 18-day period. Additionally, he was commenced on olanzapine at a dose of 5 mg orally each night at bedtime (QHS), later adjusted to 2.5 mg orally QHS. Despite two unsuccessful attempts to taper the lorazepam dosage, it was observed that the patient’s catatonic symptoms resurfaced whenever the lorazepam dosage fell below 2 mg daily, and promptly abated upon reinstating the 2 mg dosage.

Consequently, he was discharged on the 27th day, maintaining a daily lorazepam dose of 2 mg. However, following his discharge, the patient once again exhibited symptoms of mutism, diminished oral intake, negativism, closed eye, and incontinence following the use of cannabis. In accordance with the criteria delineated in DSM-5, a diagnosis of catatonia was reaffirmed, attributable to the presence of stupor, mutism, and negativism. The initial severity of his symptoms was rated as 7, based on the 23-item Bush-Francis Catatonia Rating Scale.

As a result, he was readmitted to our hospital, where a urine toxicology test once again confirmed the presence of cannabinoids. Following 3 sessions of ECT, his symptoms demonstrated notable improvement; nevertheless, 3 additional ECT sessions were deemed necessary. Subsequently, the patient was finally discharged after 19 days, devoid of any discernible symptoms. It was deduced that the periodic catatonic presentations experienced by the patient were inextricably linked to his cannabis use.

3 Discussion

In this study, we present a case of recurrent catatonia. Despite exhaustive medical and psychiatric assessments, we have been unable to elucidate the origin of this catatonic state within the framework of medical illnesses and the common psychiatric disorders often associated with catatonia, such as mood disorders and psychoses. The patient and his family have consistently denied any hallucinations, delusions, or significant mood disturbances experienced by the patient, with the exception of hypomania. Structural evaluations of the patient’s brain through both CT and MRI scans have revealed no discernible abnormalities. The sole substantial stressor evident in the patient’s history and clinical presentation is their chronic multi-drug addiction, notably, a noteworthy increase in natural cannabis consumption preceding the catatonic episodes. It is worth noting that the catatonia in this patient has shown resistance to oral and intravenous benzodiazepine treatment, necessitating the utilization of ECT to achieve significant symptom relief. Furthermore, it is noteworthy that the severity of catatonic episodes has exhibited a progressive worsening trend, with subsequent recurrences occurring at lower reported cannabis dosage levels. The causality assessment between cannabis use and the occurrence and recurrence of catatonia in this case, as evaluated using the World Health Organization - Uppsala Monitoring Centre (WHO-UMC) causality tool, is considered to be probable or likely (9).

3.1 Literature review

Although cannabis-induced catatonia is a severe and potentially life-threatening condition, considering its widespread use and its legalization for medical purposes in numerous clinical settings, the existing literature on this condition remains incomplete and inconsistent. A recent comprehensive systematic review, spanning 19 years up to 2020, revealed 14 published cases across 11 studies that establish a relationship between catatonia and cannabis or synthetic cannabinoids (SCs) (4). Furthermore, a cross-sectional study conducted by Yeoh et al. (5) examined electronic health records in London. This study successfully correlated 5.1% of catatonic episodes with substance-related causes, with the majority of cases (68 out of 108) attributed to cannabis use. These cases were observed either in the context of acute intoxication alongside chronic use (24 out of 68) or in the absence of chronic use (7 out of 68). Importantly, a significant portion of these cases showed no evidence of intoxication or withdrawal (37 out of 68) (5).

A comprehensive literature review was conducted to investigate similar cases exploring the correlation between cannabis use and catatonia. English publications up to December 2023 were retrieved by querying four electronic databases (PubMed, Scopus, Web of Science, and Google Scholar). The search involved employing different combinations of keywords, such as “cannabis” AND “catatonia,” without imposing any restrictions on these terms or their synonyms. Detailed search methodologies for each database can be found in the Supplementary materials. To identify potentially relevant articles, we explored the citations of included studies. Our focus was on reviewing case studies (case reports or case series) specifically addressing cannabis-induced catatonia. The PRISMA flow diagram in Figure 1 illustrates the process. The initial search yielded 293 articles based on the specified keywords, with EndNote automatically eliminating 46 duplicates. After screening titles and abstracts, 247 articles were excluded, resulting in 46 articles for further consideration. Following a thorough examination of full texts, 29 articles were excluded, leaving a final selection of twenty studies for inclusion in our review.

Figure 1

Figure 1. PRISMA flow diagram used for comprehensive literature search on cannabis-induced catatonia case reports.

Twenty-six patients out of twenty studies were identified, and their findings have been summarized in Table 2. Among these 26 cases, only 4 were female, constituting 84% of the sample who were male. The mean age of the patients was 22.24 ± 7.17 years old, ranging from 15 to 36 years old. Ten out of 25 cases involved pediatric patients. Additionally, it was reported that 11 cases had a history of using SCs.

Table 2

Table 2. Overview of previous reported case with cannabis-induced catatonia.

Recurrent catatonia, as observed in this case, is relatively uncommon and is not frequently reported in the literature. The majority of catatonia cases are typically episodic and resolve with appropriate treatment. The prevalence of recurrent catatonia remains uncertain due to its rarity, but it underscores the importance of studying such cases to uncover potential contributing factors. One study with a small sample size estimated catatonia recurrence to be 38.5% in bipolar disorder, based on subjective reports (30). Lin et al. performed a longitudinal study and, over 15 years, identified 30 cases of catatonia recurrences and relapses in their center, with the majority being related to a schizophrenia diagnosis (63.3%), and approximately 23.4% of patients had mood disorders. They examined the effect of a Benzodiazepine-based treatment protocol, and 79.4% of them had a full response, as in another study where almost all the patients with catatonia responded to the protocol, suggesting that recurrent catatonia may require more intervention or maintenance therapy after discharge (31, 32). Some studies claim that recurrent catatonia can be explained in the recurrent picture of mood disorders, and an underlying mood disorder may be masked behind catatonia. Due to the historical definition of catatonia, many may relate it to schizophrenia (33, 34). The recurrence of catatonia in the context of substance use, especially cannabis, is less demonstrated in the literature. Yeoh et al. (5), examined electronic health records of catatonia episodes and found an event rate of 1.46 in non-substance-related catatonia (94.9% of patients) and an event rate of 1.08 in substance-related catatonia (5.1% of patients) (5). Some of the reviewed case reports in this study provided reports of recurrence and relapses in the context of cannabis-induced catatonia (10, 16, 18, 21, 26, 29) (see Table 2). Recurrent episodes of catatonia may be a sign of an underlying psychiatric condition or triggered by various factors, including substance use or stressors. However, the pattern and pathophysiology of catatonia recurrence are under recognized in the literature. Charesworth et al. reported a similar case to our presented case, but in contrast to ours, the severity of catatonic episodes progressively became milder, and the treatment response was more desirable in the latest episodes (29).

3.2 Mechanisms for cannabis-induced catatonia

Cannabis has garnered growing interest for its potential therapeutic applications, particularly in the realm of movement disorders. A meta-analysis has concluded that cannabidiol (CBD) exerts a significant therapeutic effect on the dyskinesia and dystonia associated with Parkinsonism, and there is moderate evidence supporting its promising effects on tic disorders such as Tourette’s syndrome (35). However, another systematic review failed to provide a definitive conclusion regarding the impact of cannabis on dystonia or other motor symptoms (36). Notably, cannabis-induced catatonia presents a paradoxical situation. While cannabis is often associated with neuropsychiatric effects (37), the occurrence of cannabis-induced catatonia primarily involving motor symptoms rather than concurrent psychosis adds complexity to our comprehension. This paradox underscores the intricate interplay between cannabinoids, neural pathways, and neuropsychiatric responses, underscoring the need for further exploration and research into both the therapeutic potential and the enigmatic facets of cannabis usage in neurological and psychiatric disorders.

Research suggests that dysregulation of the endocannabinoid system may contribute to the development of catatonia in cannabis intoxication (28). The endocannabinoid system plays a critical role in motor control, as evidenced by the abundance of CB1 receptors in basal ganglia and cortical areas that modulate motor control (38). Delta-9-tetrahydrocannabinol (THC), the primary psychoactive component in cannabis, acts as a partial agonist of the CB1 receptor and can disrupt the normal activity of the endocannabinoid system (22, 38). Karniol et al. demonstrated that intraperitoneal injection of THC can induce catatonia in a dose-dependent pattern, and CBD can partially mitigate this effect (39).

Dysregulation of the endocannabinoid system is associated with a reduction in the GABAergic inhibition. The alteration in the GABAergic pathways, coupled with an increase in glutamatergic activity, can disrupt the normal functioning of the dopamine system, ultimately contributing to the manifestation of catatonia (7). The substantiation of GABAergic dysfunction’s involvement in the manifestation of catatonia is bolstered by limited observations illustrating substance-related catatonia, wherein baclofen, an agonist acting on the GABA system with effects on the central nervous system, can be associated to manifestation of catatonia (40). Catatonia has a complex pathogenesis and in the literature is associated with diverse set of mechanisms and comorbidities including systemic diseases such as autoimmune thyroiditis Ali et al. has found 13 cases in the literature with autoimmune thyroiditis and catatonia, they discussed that those systemic conditions may be underdiagnosed in the clinical settings (41).

The enduring consequences of cannabis utilization and the recurrence of cannabis-induced catatonia might possibly be correlated with the modulation of N-methyl-D-aspartate (NMDA) receptors. Anti-NMDA receptor encephalopathy is an autoimmune disease that most patients present with catatonia in the advanced stages of this disease, and has provided substantial insights into biological underpinning of catatonia (42).Cannabis, predominantly due to its psychoactive component THC, possesses the capacity to impact glutamate neurotransmission, a pivotal element in the functioning of NMDA receptors. Prolonged cannabis consumption has been connected to modifications in the density and sensitivity of NMDA receptors, potentially disrupting the delicate equilibrium of excitatory and inhibitory neurotransmission (37, 43).Chronic cannabis use is associated with instantiating neurodegenerative processes, a case report by Moshfeghinia et al. described a case with early-onset frontotemporal dementia following chronic cannabis use (44). These long lasting changes in brain structure and chemistry including perturbation in the glutamatergic system could instigate persistent alterations in neural circuitry and plasticity, thereby contributing to the continuation of catatonic symptoms beyond the acute intoxication phase (37, 42).

While cannabis use is indeed prevalent, the occurrence of cannabis-induced catatonia remains rare. This rarity can be attributed to the intricate interplay of multiple factors. Firstly, individual susceptibility plays a pivotal role, with genetic predispositions and the diathesis-stress model contributing to varying responses among users (20, 38). It’s important to note that not everyone who uses cannabis will develop catatonic symptoms. Furthermore, the psychoactive compound THC, which is abundant in many cannabis strains, is often associated with neuropsychiatric effects. However, the presence of CBD, another prominent cannabinoid in cannabis, may serve as a protective factor. CBD is believed to counterbalance some of the adverse effects of THC, potentially mitigating the risk of developing catatonia in susceptible individuals (45). This intricate interaction of genetic, environmental, and pharmacological variables underscores the complexity of cannabis-induced catatonia, rendering it an infrequent manifestation despite the widespread use of cannabis. Figure 2 summarize the mentioned pathways that cannabis can potentially change to induce catatonia.

Figure 2

Figure 2. Schematic illustration of possible mechanisms underlying cannabis-induced catatonia and its recurrence. Delta-9 tetrahydrocannabinol (THC) acts as a partial agonist for CB1R (type 1 cannabinoid receptor) that can be found in the endocannabinoid system including both Glutamatergic and GABAergic neurons. THC disrupts excitatory-inhibitory balance and dysregulated Glutamatergic and GABAergic activity dysregulate Dopaminergic activity in basal ganglia which plays a significant role in motor control, this dysregulation can manifest as catatonia. Cannabinoids are associated with changes in the density and sensitivity of NMDA receptors which can depict how THC and cannabinoids can cause long-lasting effects on brain structure and chemistry and increase a patient’s susceptibility to present with recurrent catatonia.

3.3 Limitations

This case report encountered numerous challenges and limitations. For instance, non-convulsive status epilepticus, a potential differential diagnosis for sudden onset catatonia (46), remained unexplored, with no EEG study documented during the patient’s admissions. Additionally, our case possibly overlooked the diagnosis of Anti-NMDAR encephalopathy (42). Furthermore, the confounding impact of multidrug addiction on the manifestation of catatonia in this case deserves attention. Conventional body fluid toxicology tests for cannabinoids have limitations due to cannabis narrow toxicologic window, low effective dose, the lack of test sensitivity for new marijuana formulations with less THC and more CBD and synthetic cannabinoids (11, 47). Nevertheless, it is worth noting the significant temporal association with cannabis use or overuse, which warrants reporting. This case report, along with the review of existing literature, aims to emphasize the importance of comprehending and accounting for the substantial adverse effects associated with cannabis use and prescription. Future studies and discussions are imperative to gain a deeper understanding and quantify such burdening effects of cannabis.

3.4 Future directions

Some directions for future research can be to mechanistically study the substance-induced catatonia probably using computational approaches to inform quantitative and causal relation between cannabinoids and neural dysfunction including catatonic state. As the medical use of marijuana is a developing approach in neurological and psychiatric disorders, prompt animal or simulation studies are warranted to investigate how different formulations of cannabinoids differ in case of inducing catatonia or other major psychological sequelae. One way to root for the association between cannabis use disorder and catatonia is to look for a shared genetic substrate between the two. As prior study has attempted to look at genetic risk factors related to each condition (48, 49). This knowledge is crucial for predicting and identifying susceptible individuals or formulating safer prescriptions for medical cannabinoids, as well as for promptly recognizing motor or psychotic symptoms in patients with a history of cannabis use.

4 Conclusion

Finally, the intricate relationship between the use of cannabis and the manifestation of catatonia unveils a complex phenomenon that continues to captivate our understanding. While cannabis has demonstrated numerous therapeutic advantages, particularly in the treatment of movement disorders, the emergence of catatonia in specific individuals remains an enigmatic paradox. This perplexing enigma can be attributed to a multitude of factors, including individual susceptibility, the interplay of various cannabinoids, and the intricate modulation of neurotransmitter systems, encompassing the glutamatergic, GABAergic, and dopaminergic pathways. These multifaceted mechanisms, in conjunction with genetic and environmental variables, collectively shape the diverse range of responses to cannabis and underscore the imperative for further investigation.

Data availability statement

The original contributions presented in the study are included in the article/Supplementary material, further inquiries can be directed to the corresponding authors.

Ethics statement

The studies were conducted in accordance with the local legislation and institutional requirements. The participants provided their written informed consent to participate in this study. Written informed consent was obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article.

Author contributions

RM: Conceptualization, Supervision, Writing – original draft, Writing – review & editing. MH: Writing – original draft, Writing – review & editing. SM: Investigation, Writing – original draft, Writing – review & editing. RJ: Conceptualization, Visualization, Writing – review & editing. MM: Methodology, Software, Writing – original draft, Writing – review & editing. EC: Resources, Supervision, Validation, Visualization, Writing – original draft. JA: Project administration, Validation, Visualization, Writing – review & editing.

Funding

The author(s) declare that no financial support was received for the research, authorship, and/or publication of this article.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fpsyt.2024.1332310/full#supplementary-material

References

1. Tandon, R, Heckers, S, Bustillo, J, Barch, DM, Gaebel, W, Gur, RE, et al. Catatonia in DSM-5. Schizophr Res. (2013) 150:26–30. doi: 10.1016/j.schres.2013.04.034

Crossref Full Text | Google Scholar

2. Taylor, MA, and Fink, M. Catatonia in psychiatric classification: a home of its own. Am J Psychiatr. (2003) 160:1233–41. doi: 10.1176/appi.ajp.160.7.1233

PubMed Abstract | Crossref Full Text | Google Scholar

3. Edinoff, AN, Kaufman, SE, Hollier, JW, Virgen, CG, Karam, CA, Malone, GW, et al. Catatonia: clinical overview of the diagnosis, treatment, and clinical challenges. Neurol Int. (2021) 13:570–86. doi: 10.3390/neurolint13040057

PubMed Abstract | Crossref Full Text | Google Scholar

4. Palma-Alvarez, RF, Soriano-Dia, A, Ros-Cucurull, E, Daigre, C, Serrano-Perez, P, Ortega-Hernandez, G, et al. Catatonia related to cannabis and synthetic cannabinoids: a review. J Dual Diagn. (2021) 17:159–71. doi: 10.1080/15504263.2021.1904163

PubMed Abstract | Crossref Full Text | Google Scholar

5. Yeoh, SY, Roberts, E, Scott, F, Nicholson, TR, David, AS, and Rogers, JP. Catatonic episodes related to substance use: a cross-sectional study using electronic healthcare records. J Dual Diagn. (2022) 18:52–8. doi: 10.1080/15504263.2021.2016342

PubMed Abstract | Crossref Full Text | Google Scholar

6. Daniels, J. Catatonia: clinical aspects and neurobiological correlates. J Neuropsychiatry Clin Neurosci. (2009) 21:371–80. doi: 10.1176/jnp.2009.21.4.371

PubMed Abstract | Crossref Full Text | Google Scholar

7. Northoff, G. What catatonia can tell us about “top-down modulation”: a neuropsychiatric hypothesis. Behav Brain Sci. (2002) 25:555–77. doi: 10.1017/S0140525X02000109

PubMed Abstract | Crossref Full Text | Google Scholar

8. Zou, S, and Kumar, U. Cannabinoid receptors and the endocannabinoid system: signaling and function in the central nervous system. Int J Mol Sci. (2018) 19. doi: 10.3390/ijms19030833

PubMed Abstract | Crossref Full Text | Google Scholar

9. WHO. The use of the WHO–UMC system for standardised case causality assessment [Internet]. Geneva: World Health Organization (2020).

Google Scholar

10. Bajaj, V, Pathak, P, Mehrotra, S, Singh, V, Govil, S, and Khanna, A. Cannabis induced periodic catatonia: a case report. Int J Ment Heal Addict. (2011) 9:162–4. doi: 10.1007/s11469-009-9262-9

Crossref Full Text | Google Scholar

11. Cohen, J, Morrison, S, Greenberg, J, and Saidinejad, M. Clinical presentation of intoxication due to synthetic cannabinoids. Pediatrics. (2012) 129:e1064–7. doi: 10.1542/peds.2011-1797

Crossref Full Text | Google Scholar

12. Leibu, E, Garakani, A, McGonigle, DP, Liebman, LS, Loh, D, Bryson, EO, et al. Electroconvulsive therapy (ECT) for catatonia in a patient with schizophrenia and synthetic cannabinoid abuse: a case report. J ECT. (2013) 29:e61–2. doi: 10.1097/YCT.0b013e318290fa36

PubMed Abstract | Crossref Full Text | Google Scholar

13. Haro, G, Ripoll, C, Ibáñez, M, Orengo, T, Liaño, VM, Meneu, E, et al. Could spice drugs induce psychosis with abnormal movements similar to catatonia? Psychiatry. (2014) 77:206–8. doi: 10.1521/psyc.2014.77.2.206

PubMed Abstract | Crossref Full Text | Google Scholar

14. Smith, DL, and Roberts, C. Synthetic marijuana use and development of catatonia in a 17-year-old male. Minn Med. (2014) 97:38.

Google Scholar

15. Caudron, M, Rolland, B, Deheul, S, Geoffroy, PA, Thomas, P, and Amad, A. Catatonia and cannabis withdrawal: a case report. Subst Abus. (2016) 37:188–9. doi: 10.1080/08897077.2015.1052869

PubMed Abstract | Crossref Full Text | Google Scholar

16. Håkansson, A, and Johansson, BA. Atypical course in severe catatonic schizophrenia in a cannabis-dependent male adolescent: a case report. J Med Case Rep. (2015) 9:1–5. doi: 10.1186/s13256-015-0678-5

Crossref Full Text | Google Scholar

17. Khan, M, Pace, L, Truong, A, Gordon, M, and Moukaddam, N. Catatonia secondary to synthetic cannabinoid use in two patients with no previous psychosis. Am J Addict. (2016) 25:25–7. doi: 10.1111/ajad.12318

PubMed Abstract | Crossref Full Text | Google Scholar

18. Roberto, AJ, Lorenzo, A, Li, KJ, Young, J, Mohan, A, Pinnaka, S, et al. First-episode of synthetic cannabinoid-induced psychosis in a young adult, successfully managed with hospitalization and risperidone. Case reports. Psychiatry. (2016) 2016:1–4. doi: 10.1155/2016/7257489

Crossref Full Text | Google Scholar

19. Pierre, JM, Gandal, M, and Son, M. Cannabis-induced psychosis associated with high potency “wax dabs”. Schizophr Res. (2016) 172:211–2. doi: 10.1016/j.schres.2016.01.056

PubMed Abstract | Crossref Full Text | Google Scholar

20. Keller, CJ, Chen, EC, Brodsky, K, and Yoon, JH. A case of butane hash oil (marijuana wax)–induced psychosis. Subst Abus. (2016) 37:384–6. doi: 10.1080/08897077.2016.1141153

PubMed Abstract | Crossref Full Text | Google Scholar

21. Williams, DR, Miller, BJ, Tatugade, A, Avasthi, R, and Buckley, PF. Unresponsive and mute after he smoked ‘spice’. Curr Psychiatr Ther. (2016) 15:65.

Google Scholar

22. Bulbena-Cabre, A, DiGenova, P, Sigel, P, Dunn, NR, and Swift, RG. Synthetic cannabinoid intoxication presenting as malignant catatonia: a case report. Int J Ment Heal Addict. (2020) 18:582–6. doi: 10.1007/s11469-018-9954-0

Crossref Full Text | Google Scholar

23. Manning, T, Bartow, C, McNaughton, M, Reynolds, E, and Chen, Z. Vaping cannabis oil: a case of catatonia associated with use of high-potency cannabis. Psychosomatics. (2020) 61:745–51. doi: 10.1016/j.psym.2020.06.012

PubMed Abstract | Crossref Full Text | Google Scholar

24. Mekala, H, Malik, Z, Lone, J, Shah, K, and Ishaq, M. Cannabis-induced catatonia: a case series. Cureus. (2020) 12:6. doi: 10.7759/cureus.8603

Crossref Full Text | Google Scholar

25. Sheikh, B, Hirachan, T, Gandhi, K, Desai, S, Arif, R, Isakov, O, et al. Cannabis-induced malignant catatonia: a medical emergency and review of prior case series. Cureus. (2021) 13. doi: 10.7759/cureus.17490

Crossref Full Text | Google Scholar

26. Gouse, BM, Nieves-Archibald, A, Trutzer, I, Rezvani, M, Srinath, M, Chang, A, et al. Pediatric malignant catatonia associated with vaporized cannabis use: a case series. J Acad Consult Liaison Psychiatry. (2021) 62:445–8. doi: 10.1016/j.jaclp.2021.02.004

PubMed Abstract | Crossref Full Text | Google Scholar

27. Palkar, P, and Ray, S. An atypical case of catatonia, abnormal gait and psychosis in an adolescent with chronic Cannabis use. J Drugs Addict Therapeut. (2021) 2:1–3. doi: 10.47363/JDAT/2021(2)114

Crossref Full Text | Google Scholar

28. Gauthier, T, Prakash, PB, Drew Keopple, N, and Vardis, R. Cannabis-induced catatonia in a 15-year-old male: a case report. WMJ. (2023) 132

Google Scholar

29. Charlesworth, JE, Ghosn, O, Hussain, N, Mahmoud, R, Goncalves, V, and Godbole, M. A case report of an unusual presentation of a patient with recurrent idiopathic catatonia. Psychiatry Res Case Rep. (2023) 2:100111. doi: 10.1016/j.psycr.2023.100111

Crossref Full Text | Google Scholar

30. Medda, P, Toni, C, Luchini, F, Giorgi Mariani, M, Mauri, M, and Perugi, G. Catatonia in 26 patients with bipolar disorder: clinical features and response to electroconvulsive therapy. Bipolar Disord. (2015) 17:892–901. doi: 10.1111/bdi.12348

PubMed Abstract | Crossref Full Text | Google Scholar

31. Lin, C-C, Hung, Y-Y, Tsai, M-C, and Huang, T-L. Relapses and recurrences of catatonia: 30-case analysis and literature review. Compr Psychiatry. (2016) 66:157–65. doi: 10.1016/j.comppsych.2016.01.011

PubMed Abstract | Crossref Full Text | Google Scholar

32. Lin, C-C, and Huang, T-L. Lorazepam–diazepam protocol for catatonia in schizophrenia: a 21-case analysis. Compr Psychiatry. (2013) 54:1210–4. doi: 10.1016/j.comppsych.2013.06.003

PubMed Abstract | Crossref Full Text | Google Scholar

33. Fein, S, and McGrath, MG. Problems in diagnosing bipolar disorder in catatonic patients. J Clin Psychiatry. (1990) 51:203–5.

PubMed Abstract | Google Scholar

34. Nath, S, Bhoi, R, Mishra, B, and Padhy, S. Does recurrent catatonia manifest in a similar fashion in all the episodes of mood disorder? A case series with literature review. Gen Psychiatry. (2021) 34. doi: 10.1136/gpsych-2021-100494

Crossref Full Text | Google Scholar

35. Bilbao, A, and Spanagel, R. Medical cannabinoids: a pharmacology-based systematic review and meta-analysis for all relevant medical indications. BMC Med. (2022) 20:259. doi: 10.1186/s12916-022-02459-1

PubMed Abstract | Crossref Full Text | Google Scholar

36. Oikonomou, P, and Jost, W. Randomized controlled trials on the use of cannabis-based medicines in movement disorders: a systematic review. J Neural Transm. (2022) 129:1247–56. doi: 10.1007/s00702-022-02529-x

PubMed Abstract | Crossref Full Text | Google Scholar

37. Sánchez-Blázquez, P, Rodríguez-Muñoz, M, and Garzón, J. The cannabinoid receptor 1 associates with NMDA receptors to produce glutamatergic hypofunction: implications in psychosis and schizophrenia. Front Pharmacol. (2014) 4:169. doi: 10.3389/fphar.2013.00169

Crossref Full Text | Google Scholar

38. Sideli, L, Quigley, H, La Cascia, C, and Murray, RM. Cannabis use and the risk for psychosis and affective disorders. J Dual Diagn. (2020) 16:22–42. doi: 10.1080/15504263.2019.1674991

Crossref Full Text | Google Scholar

39. Karniol, I, and Carlini, E. Pharmacological interaction between cannabidiol and Δ 9-tetrahydrocannabinol. Psychopharmacologia. (1973) 33:53–70. doi: 10.1007/BF00428793

Crossref Full Text | Google Scholar

40. Rissardo, JP, Konduru, SN, Gadamidi, VK, and Caprara, ALF. Baclofen and catatonia: a case report. Pan Afr Med J. (2022) 43:43. doi: 10.11604/pamj.2022.43.198.38403

Crossref Full Text | Google Scholar

41. Ali, HT, Mohamed, FR, Al-Ghannami, AK, Caprara, ALF, and Rissardo, JP. Catatonia as the presentation of encephalopathy associated with autoimmune thyroiditis: a case report and literature review. J Psychiatr Pract. (2023) 29:499–504. doi: 10.1097/PRA.0000000000000751

PubMed Abstract | Crossref Full Text | Google Scholar

42. Parenti, A, Jardri, R, and Geoffroy, PA. How anti-NMDAR encephalitis sheds light on the mechanisms underlying catatonia: the neural excitatory/inhibitory imbalance model. Psychosomatics. (2016) 57:336–8. doi: 10.1016/j.psym.2016.01.007

PubMed Abstract | Crossref Full Text | Google Scholar

43. Rivas-Santisteban, R, Lillo, A, Lillo, J, Rebassa, J-B, Contestí, JS, Saura, CA, et al. N-Methyl-D-aspartate (NMDA) and cannabinoid CB 2 receptors form functional complexes in cells of the central nervous system: insights into the therapeutic potential of neuronal and microglial NMDA receptors. Alzheimers Res Ther. (2021) 13:1–15. doi: 10.1186/s13195-021-00920-6

Crossref Full Text | Google Scholar

44. Moshfeghinia, R, Oji, B, Hosseinzadeh, M, Pourfridoni, M, and Ahmadi, J. Early onset frontotemporal dementia following cannabis abuse: a case report. BMC Psychiatry. (2023) 23:484. doi: 10.1186/s12888-023-04956-w

PubMed Abstract | Crossref Full Text | Google Scholar

45. McPartland, JM, Duncan, M, Di Marzo, V, and Pertwee, RG. Are cannabidiol and Δ9-tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review. Br J Pharmacol. (2015) 172:737–53. doi: 10.1111/bph.12944

PubMed Abstract | Crossref Full Text | Google Scholar

46. Gadelho, LS, and Marques, JG. Catatonia associated with epileptic seizures: a systematic review of case reports. Epilepsy Res. (2022) 186:107016. doi: 10.1016/j.eplepsyres.2022.107016

Crossref Full Text | Google Scholar

47. Johnson, OE, Miskelly, GM, and Rindelaub, JD. Testing for cannabis intoxication: current issues and latest advancements. Wiley Interdiscipl Rev. (2022) 4:e1450. doi: 10.1002/wfs2.1450

Crossref Full Text | Google Scholar

48. Wilson, JE, Sealock, J, Straub, P, Raman, R, Kipp, AM, Dittus, RS, et al. Exploring genetic risk for catatonia in a genome wide association study and polygenic risk score analysis. Schizophr Res. (2023) 263:178–90. doi: 10.1016/j.schres.2023.07.015

Crossref Full Text | Google Scholar

49. Hillmer, A, Chawar, C, Sanger, S, D’Elia, A, Butt, M, Kapoor, R, et al. Genetic basis of cannabis use: a systematic review. BMC Med Genet. (2021) 14:1–21. doi: 10.1186/s12920-021-01035-5

Crossref Full Text | Google Scholar